Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tempus AI, Inc. - Class A Common Stock (NQ:TEM)

78.45 +4.67 (+6.33%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tempus AI, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Tempus AI Strikes $200M Deal With AstraZeneca, Pathos To Build World's Largest Oncology Model
The biggest strategic highlight for Tempus AI Inc. (NASDAQ: TEM) during the first quarter was a multi-million dollar deal to build "the world's largest foundation model for oncology." 
Via Benzinga
Topics Artificial Intelligence
Tempus AI Q1 Earnings: Revenue Beat, EPS Beat, Raised FY Guidance, Shares Surge
Tempus AI reports first-quarter revenue of $255.74 million, beating estimates of $248.13 million. The AI-focused precision medicine and patient care company reports a first-quarter adjusted loss of 24... 
Via Benzinga
Topics Artificial Intelligence
Tempus Reports First Quarter 2025 Results
From Tempus AI, Inc.
Via Business Wire
Tempus AI (TEM) Stock Lower Ahead Of Q1 Earnings Report, Notetaker AI Debut
Tempus AI shares are trading lower by 1.3% Tuesday afternoon. The company will report its Q1 earnings after Tuesday's market close. 
Via Benzinga
Topics Artificial Intelligence
Earnings Scheduled For May 6, 2025
 
Via Benzinga
Tempus Announces Notetaker, its AI-Powered Clinical Assistant for Psychiatry
From Tempus AI, Inc.
Via Business Wire
Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time.
Via The Motley Fool
Topics Artificial Intelligence
Jim Cramer: Sunrun Had 'Bad Couple Of Quarters,' ExlService Holdings Is 'Solid'
On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying BlackRock, Inc. because "it's going to be a great position." 
Via Benzinga
Tempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and Enrollment
From Tempus AI, Inc.
Via Business Wire
Is This the Best Nancy Pelosi Stock to Buy After a 40% Pullback?
Via The Motley Fool
Topics Artificial Intelligence
Tempus Publishes Study Validating the Benefits of xF+, its Comprehensive Liquid Biopsy Assay for Therapy Selection
From Tempus AI, Inc.
Via Business Wire
Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:TEM),(NASDAQ:POAI),(NASDAQ:ADMA) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Tempus Introduces Loop, an AI-Powered Target Discovery and Validation Platform
From Tempus AI, Inc.
Via Business Wire
Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth
From FN Media Group LLC
Via GlobeNewswire
Bitdeer Tech And Tempus AI Are Among Top 18 Mid-Cap Gainers Last Week (Apr 21-Apr 25): Are The Others In Your Portfolio?
Top mid-cap stock performers last week: Ascentage Pharma, Ardagh Metal, Bitdeer Tech, Pegasystems, Impinj, Lufax, Tempus AI, Kymera Therapeutics. 
Via Benzinga
Topics Artificial Intelligence
Tempus Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025
From Tempus AI, Inc.
Via Business Wire
Tempus to Report First Quarter 2025 Financial Results on May 6
From Tempus AI, Inc.
Via Business Wire
Beyond The Numbers: 9 Analysts Discuss Tempus AI Stock
 
Via Benzinga
Topics Artificial Intelligence
Tempus AI Is Skyrocketing Today -- Is the Stock a Buy Right Now?
Via The Motley Fool
Topics Artificial Intelligence Government Stocks
Tempus AI Stock Is Ripping Higher Wednesday: What's Fueling The Move?
Tempus AI Inc (NASDAQ:TEM) shares are surging Wednesday after the company announced a multi-year collaboration with AstraZeneca PLC (NASDAQ:AZN) and Pathos AI. 
Via Benzinga
Topics Artificial Intelligence
Tempus AI Stock Surges Nearly 16% on Strategic Partnerships and AI-Driven Oncology Breakthroughs
April 23, 2025 – Tempus AI, Inc. (NASDAQ: TEM), a leading precision medicine company leveraging artificial intelligence (AI) for diagnostic and therapeutic advancements, saw its Class A Common Stock... 
Via MarketMinute
Topics Artificial Intelligence Stocks World Trade
Why Tempus AI Stock Is Skyrocketing Today
Via The Motley Fool
Topics Artificial Intelligence
Amphenol Posts Better-Than-Expected Results, Joins SAP, Tesla, Pegasystems And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology
From Tempus AI, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Tempus Unveils Advisory Board Featuring Leading Physicians From Across the U.S.
From Tempus AI, Inc.
Via Business Wire
Global AI Diagnostics Market to Reach $8.54 Billion By 2033 as Industry Sees Increasing R&D and Strategic Collaborations
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:ILMN),(NASDAQ:TEM),(NYSE:MDT),(NASDAQ:MDAI) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Global AI Diagnostics Market to Reach $8.54 Billion By 2033 as Industry Sees Increasing R&D and Strategic Collaborations
From FN Media Group LLC
Via GlobeNewswire
3 Hot New IPOs Defying the 2025 Market Slump
Tempus AI, ServiceTitan, and CoreWeave are 2025 IPO standouts, defying a down market. Here’s how they’re beating the S&P 500 so far this year. 
Via MarketBeat
Topics Artificial Intelligence Initial Public Offering Stocks
Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing
FDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective and human relevant methods. 
Via Benzinga
Topics Animal Testing
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.